BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

943 related articles for article (PubMed ID: 15661543)

  • 21. Acute and delayed nausea and emesis control in pediatric oncology patients.
    Holdsworth MT; Raisch DW; Frost J
    Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents.
    Smith AR; Repka TL; Weigel BJ
    Pediatr Blood Cancer; 2005 Nov; 45(6):857-60. PubMed ID: 15849684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
    Perez EA
    Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy?
    Schwartzberg LS
    Oncology (Williston Park); 2007 Jul; 21(8):946-53; discussion 954, 959, 962 passim. PubMed ID: 17715696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment--how are we doing?
    Grunberg SM
    J Support Oncol; 2004; 2(1 Suppl 1):1-10, inside back cover; quiz 11. PubMed ID: 16117016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Prevention and control of chemotherapy-induced nausea and vomiting].
    Gómez-Raposo C; Feliú-Batlle J; González-Baróna M
    Med Clin (Barc); 2006 Feb; 126(4):143-51. PubMed ID: 16472500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy-induced nausea and vomiting in the treatment of gastrointestinal tumors and secondary prophylaxis with aprepitant.
    Abbrederis K; Lorenzen S; Rothling N; Ihbe-Heffinger A; Schuster T; Peschel C; Lordick F
    Onkologie; 2009 Feb; 32(1-2):30-4. PubMed ID: 19209016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009.
    Jordan K; Roila F; Molassiotis A; Maranzano E; Clark-Snow RA; Feyer P;
    Support Care Cancer; 2011 Mar; 19 Suppl 1():S37-42. PubMed ID: 20824481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Carides G; Elmer M; Schmidt C; Evans JK; Horgan KJ
    J Clin Oncol; 2003 Nov; 21(22):4105-11. PubMed ID: 14559891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.
    Trigg ME; Higa GM
    J Oncol Pharm Pract; 2010 Dec; 16(4):233-44. PubMed ID: 20085961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
    Cunningham RS
    Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only).
    Roila F; Warr D; Aapro M; Clark-Snow RA; Einhorn L; Gralla RJ; Herrstedt J; Saito M; Tonato M
    Support Care Cancer; 2011 Mar; 19 Suppl 1():S57-62. PubMed ID: 21132332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical roundtable monograph. Treatment of chemotherapy-induced nausea and vomiting: a post-MASCC 2010 discussion.
    Kris MG; Urba SG; Schwartzberg LS
    Clin Adv Hematol Oncol; 2011 Jan; 9(1):suppl 1-15. PubMed ID: 21370520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimising antiemetic therapy: what are the problems and how can they be overcome?
    Aapro M
    Curr Med Res Opin; 2005 Jun; 21(6):885-97. PubMed ID: 15969889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of palonosetron: emerging data distinguishing it as a novel 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting.
    Saito M; Tsukuda M
    Expert Opin Pharmacother; 2010 Apr; 11(6):1003-14. PubMed ID: 20307224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
    Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
    J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of neurokinin-1 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy.
    Rogers MP; Blackburn L
    Clin J Oncol Nurs; 2010 Aug; 14(4):500-4. PubMed ID: 20682506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiemetics: an update and the MASCC guidelines applied in clinical practice.
    Herrstedt J
    Nat Clin Pract Oncol; 2008 Jan; 5(1):32-43. PubMed ID: 18097455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.